SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2023
Commission File Number: 001-41421
(Translation of registrant's name into English)
9, Rue de Bitbourg,
Grand Duchy of Luxembourg
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ] Form 40-F [ ]
On November 15, 2023, Alvotech issued an Announcement to the Nasdaq Iceland Main Market, disclosed according to the rules of the exchange. A copy of the Announcement is furnished herewith as exhibit 99.1.
|99.1||Press Release dated November 15, 2023|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
|Date: November 15, 2023||/s/ Tanya Zharov|
Alvotech Accepts Offer to Sell its Subsidiary in Hannover, Germany
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today that it has accepted the offer of a subsidiary of Light Curve Capital Holdings Pte. Ltd for all shares of Alvotech's subsidiary, Alvotech Hannover GmbH.
Alvotech Hannover GmbH, which operates laboratories in Hannover, Germany specializes in providing analytical protein characterization. Alvotech has developed the capability to perform these analytical methods in its R&D facilities in Iceland.
The transaction is subject to customary closing conditions, to be completed in early 2024.
Alvotech Investor Relations